Results 31 to 40 of about 255,512 (289)

Nephrotoxicity of checkpoint inhibitors; a current challenge [PDF]

Journal of Nephropharmacology
Immune checkpoint inhibitors work by blocking the "checkpoint" mechanism that tumors use to hide from the immune system, therefore also weakening the immune system.
Samaneh Zandifar, Mahshid Imankhan, Padideh Daneii, Ali Azarpey, Leila Alem   +4 more
doaj   +1 more source

Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy

Vaccines, 2023
Hepatitis B virus (HBV) infection is the main risk factor for the development of hepatocellular carcinoma (HCC), the most common type of liver cancer, with high incidence and mortality worldwide.
Jin Zhang, Changwei Hu, Xiaoxiao Xie, Linzhi Qi, Chuanzhou Li, Shangze Li   +5 more
doaj   +1 more source

Oncologic Emergencies: Immune-Based Cancer Therapies and Complications [PDF]

, 2020
Cancer therapies have undergone several recent advancements. Current cancer treatments include immune-based therapies comprised of checkpoint inhibitors, and adoptive immunotherapy; each treatment has the potential for complications that differ from ...
Brém, Elizabeth, Koyfman, Alex, Long, Brit Jeffrey   +2 more
core  

Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management

Kidney Medicine, 2021
Immune checkpoint inhibitors are now approved for more than 50 indications, and increasing numbers of patients with advanced cancer are receiving immunotherapy.
Harish Seethapathy, Sandra M. Herrmann, Meghan E. Sise   +2 more
doaj   +1 more source

FOXD3 Regulates VISTA Expression in Melanoma. [PDF]

, 2020
Immune checkpoint inhibitors have improved patient survival in melanoma, but the innate resistance of many patients necessitates the investigation of alternative immune targets.
Aplin, Andrew E., Berger, Adam C., Chervoneva,, Davies, Michael A., Erkes, Dan A., Fisher, David E., Gershenwald, Jeffrey E., Knecht, Meghan, Lo, Jennifer A., McCue, Peter A., Mollaee, Mehri, Purwin, Timothy J., Rosenbaum, Sheera R., Zhong, Zhijiu   +13 more
core   +1 more source

Cardiotoxicity of immune checkpoint inhibitors [PDF]

, 2017
Cardiac toxicity after conventional antineoplastic drugs (eg, anthracyclines) has historically been a relevant issue. In addition, targeted therapies and biological molecules can also induce cardiotoxicity.
Allison, Atkins, Azuma, Azuma, Baban, Badros, Bellmunt, Bloom, Borghaei, Boussiotis, Boutros, Brahmer, Brahmer, Bretscher, Brunet, Buchbinder, Cardinale, Cardinale, Chen, Chen, Chen, Cooper, Corsello, Costa, Ding, Dong, Dong, Douglas, Dyck, Eigentler, Fehrenbacher, Francisco, Freeman, Freeman, Gagliani, Gangadhar, Garon, Gay, Geisler, Gibson, Goodman, Gordon, Grabie, Hamanishi, Hamid, Hamo, Han, Hathcock, Heinzerling, Herbst, Herbst, Hodi, Hofmann, Huang, Hurst, Jain, Johnson, Johnson, Johnston, Keir, Khan, Koelzer, Lacouture, Larkin, Lasaro, Latchman, Le Mercier, Le Mercier, Leach, Lesokhin, Lines, Linsley, Linsley, Lucas, Läubli, Mahoney, Martin, Matsuzaki, Menzies, Michot, Mohme, Moslehi, Moynihan, Naidoo, Nayak, Nghiem, Nguyen, Ni, Nishimura, Nishimura, Okamura, Okazaki, Okazaki, Pardoll, Peggs, Pitt, Postow, Powles, Prashanth, Ribas, Rittmeyer, Rizvi, Robert, Robert, Roth, Sakuishi, Semper, Sharma, Sharma, Sheppard, Sivan, Smyth, Spain, Stanietsky, Suter, Tadokoro, Tadokoro, Tarrio, Tivol, Tocchetti, Tocchetti, Topalian, Topalian, Tumeh, Voskens, Vétizou, Wang, Wang, Watanabe, Waterhouse, Weber, Westin, Wing, Wolchok, Woo, Yan, Yeh, Yokosuka, Yu, Yun, Zitvogel   +140 more
core   +1 more source

Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration [PDF]

, 2020
Background Immune checkpoint inhibitors such as nivolumab and targeted BRAF inhibitors have dramatically altered the treatment outcomes of metastatic melanoma over the past few years. Skin toxicity is the most common adverse event (AE) related to the
Maestro, Alessandra, Marcuzzi, Annalisa, Maximova, Natalia, Zanon, Davide   +3 more
core   +1 more source

Adverse effects of immune checkpoint inhibitor therapies on right ventricular function and pulmonary arterial dilatation

Pulmonary Circulation, 2021
Immunologic risk factors contribute to endothelial dysfunction and development of pulmonary vascular disease. Immune checkpoint inhibitors, used as immunotherapies for malignancies, have a wide range of reported immune-related adverse events.
Ruben Mylvaganam, Ryan Avery, Isaac Goldberg, Courtney Makowski, Ravi Kalhan, Victoria Villaflor, Michael J. Cuttica   +6 more
doaj   +1 more source

Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy [PDF]

, 2017
Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal antibodies (MAbs) developed for cancer immunotherapy.
Mai, Antonello, Mazzone, Roberta, Valente, Sergio, Zwergel, Clemens   +3 more
core   +1 more source

Operative management of immune checkpoint colitis following in-transit melanoma: Case report

Frontiers in Oncology, 2023
Immune checkpoint inhibitors are increasingly used as powerful anti-neoplastic therapies in the setting of melanoma. Colitis is a known complication of immune checkpoint inhibitors that if often medically managed.
Betzaira G. Childers, Eileen Donovan, Winifred M. Lo, Lauren M. Janowak, Jeffrey Sussman, Christopher F. Janowak   +5 more
doaj   +1 more source